Recent headlines from the sources AlphaScala monitors. AlphaScala analysis is published in the main market section.
Lexicon Pharmaceuticals published its Q1 2026 earnings presentation. Investors focus on pipeline updates and cash runway as the deck sets up the next catalyst for LXRX.
Miller Industries Q1 revenue hit $298M, gross margin expanded 230 bps to 14.8%. Towing demand and stable steel costs drove the beat. Free cash flow of $14M supports dividend outlook.
House leaders urge Trump to nominate CFTC members, citing the CLARITY Act. Without a full panel, crypto oversight may stall as the bill advances.
Jim Cramer says the bond market is in control as Treasury yields hit one-year highs and oil surges. With Nvidia, Walmart, and others reporting, the macro transmission is the key risk.
Anthropic's Claude Design AI tool launched in April. Figma responded by raising its full-year outlook. The raise signals confidence in its AI strategy despite new competition.
Tree Island Steel's AGM drew 66.32% of shares, re-electing all directors. The high turnout signals engaged shareholders as the company's focus shifts to Q2 operational performance.
BCDA Q1 call set CardiAMP Japan PMDA timeline: ~7-month filing then ~19-month review. The stock is a binary bet on that regulatory path and funding through it.
Skeena's Q1 2026 filing reaffirms Q2 2027 first production at Eskay Creek. The absence of cash balance or construction updates leaves traders with binary execution risk.
Federal probe into BlackRock's private credit marks could pressure BLK stock and test investor confidence in the private lending market.
Siebert Financial reported a Q1 net loss of $2.0 million, reversing a $8.7 million profit a year ago. Revenue of $23.5M masks underlying cost pressures. Next catalyst: expense trajectory.
Allarity Therapeutics reported Q1 EPS -$0.17, beating by $0.05. Cash of $29.8M sets a finite runway. The stock's next move depends on pipeline progress and the 10-Q cash burn details.
iQIYI reports Q1 2026 Monday before open. Consensus loss $0.03/sh, revenue $920M. Subscriber trend and AI cost savings decide the stock's direction.
Meme coin portfolios fell 50–80% in 2025. Capital now flows into tokens under $50M market cap with thin liquidity. Next catalyst: CLARITY Act Senate vote.
Syntec Optics' Q1 revenue of $6.5M, down 8.5% YoY, and a GAAP loss of $0.02 per share raise cash burn concerns for the micro-cap optics maker. The 10-Q filing will be the next catalyst.
ValueAct's Q1 13F reveals new KKR, Spotify positions alongside exits from Disney and Insight. The rotation signals sector tilts toward asset management and streaming.
Birchcliff Energy shareholders reelected all seven directors, confirming board continuity for the Montney-focused producer. The vote removes a governance distraction, leaving natural gas prices and well productivity as the next catalysts.
Myanmar's military junta introduces draft law enabling life imprisonment and possible death penalty for large-scale crypto fraud linked to Southeast Asian scam compounds.
Revolut secures FCA approval for private wealth and leveraged products, pairing with its crypto licence and UK banking charter. The £500k entry point targets an underserved segment between Coutts and retail.
DBS analysts see Singapore's non-oil domestic exports extending gains on AI demand, supporting the SGD. The next NODX print and MAS October policy statement are key catalysts.
Citius Q2: GAAP EPS of -$0.95, product revenue $1.7M. This first quarter of commercial sales sets up a cash-burn vs revenue trajectory test for CTXR.
RedStone's Settle layer aims to tokenize real-world assets for DeFi collateral. No partnerships or regulatory sign-off yet. The $30B target faces execution risk.
a16z calls the CLARITY Act's May 14 Senate Banking vote a potential 1933 moment, replacing enforcement with statutory rules for digital asset markets.
Dan Loeb's Third Point dumped Microsoft and Nvidia while adding Meta and Alphabet. The 13F reveals a bet on AI monetization over chip supply.
MiNK Therapeutics initiates 90-patient randomized Phase II ARDS trial; initial data in 2H 2026 creates a binary catalyst for INKT stock.
MiNK Therapeutics presented Phase II gastric data at AACR and IPF findings at Keystone. The stock's next move depends on partnership interest and cash runway.
ExxonMobil hit a record high of $176.41 after Q4 earnings beat on 4.7M boe/d production. The $20B buyback plan and 2030 earnings target of $25B set the forward case.
ING analysts flag widening gap between consumer inflation and GDP as energy costs erode real incomes. Yen remains under pressure as BoJ faces stagflationary dilemma.
PMI data from major economies will set the tone for central bank guidance, with EUR/USD and USD/JPY facing key positioning tests after extreme COT bets.
Bitcoin and Ethereum lead $388M derivatives unwind; funding rates reset over 48-72 hours will reveal if this is a healthy flush or the start of deeper drawdown.
Land & Buildings' Q1 13F shows a rotation out of storage and into single-family rental and data centers. The activist fund added INVH, exited NSA, and boosted DLR. AlphaScala scores all three REITs as Mixed, suggesting the trade is not a consensus call.